Aspirin after hospitalisation with Pneumonia to prevent cardiovascular Events randomised Controlled Trial (ASPECT)

orth Bristol NHS Trust0 个研究点目标入组 22,600 人开始时间: 2022年11月3日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1. Aged 50 years and over, and
•2. Symptoms and signs of acute lower respiratory tract infection, and
•3. Radiographic changes in keeping with infection on chest radiograph, CT scan or lung ultrasound scan

•1. Already taking regular prescribed anti-platelet medication, including aspirin, clopidogrel, cangrelor, selexipag, cilostazol, dipyridamole, prasugrel, ticagrelor, abciximab, eptifibatide, tirofiban, epoprostenol, iloprost;
•2. A known allergy, previous important adverse reaction, or contraindication to aspirin;
•3. At high risk of excessive bleeding (e.g. large trauma or haemorrhage or urgent need for major surgery or uncorrectable coagulopathy) in the opinion of the treating physician;
•4. Hospital acquired pneumonia, defined as related to an inpatient hospital stay within the last 10 days or acquired at least 48 hours after current admission;
•5. Discharged without a ‘Decision to Admit’ to hospital by urgent care/emergency department
•6. Unlikely to tolerate/adhere to medication regimen;
•7. Prisoners;
•8. Known to be pregnant;
•9. Life expectancy <3 months due to pre-existing condition (e.g. terminal malignancy);
•10. Presentation more likely due to acute COVID-19 pneumonitis in the opinion of the treating physician. i.e. newly positive Polymerase Chain Reaction (PCR) or similar antigen test for COVID-19;
•11. Enrolment onto another study where the burden on the participant will be too high if they are enrolled onto to both. Or, if the enrolment onto both would compromise one or both of the study’s objectives. To be decided on a case-by-case basis.

发起方

orth Bristol NHS Trust